Pfizer's C. difficile Vaccine Succeeds in Phase II Study
February 2nd 2017Researchers found the experimental vaccine could potentially inhibit severe diarrhea and pseudomembranous colitis by inducing a functional antibody response that can neutralize the two main disease-causing toxins (toxin A or B) produced by C. difficile.
Read More